Novel biomarkers in autoimmune diseases - Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases
Novel biomarkers in autoimmune diseases - Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases
复制标题
DOI：
10.1196/annals.1398.044
复制
发表时间：
2007-01-01
期刊：
影响因子：
--
通讯作者：
Shoenfeld, Yehuda
中科院分区：
文献类型：
--
作者：
Orbach, Hedi;Zandman-Goddard, Gisele;Shoenfeld, Yehuda
自身免疫性疾病的发展可能受到激素、免疫调节和代谢途径的影响。在自身免疫性疾病中测量催乳素 (PRL)、铁蛋白、维生素 D 和肿瘤标志物组织多肽抗原 (TPA)：系统性红斑狼疮 (SLE)、系统性硬化症 (SSc)、类风湿性关节炎 (RA)、多发性肌炎 (PM)、皮肌炎 (DM)、多发性硬化症 (MS)、 抗免疫甲状腺疾病和抗磷脂综合征。高泌乳素血症 (HPRL) 在 PM 患者中检测到，21% 在 SLE 患者中检测到，在 MS 患者中检测到 6.7%，在 RA 患者中检测到 6%，在 SSc 患者中检测到 3%。 23%的SLE患者、15%的DM患者、8%的MS患者和4%的RA患者检测到高铁蛋白血症。患者的 25 OH 维生素 D 水平相对较低：不同疾病的平均结果（平均值 +/- SD）在 9.3 +/- 4.4 至 13.7 +/- 7.1 ng/mL 之间，而 25 OH 维生素 D 浓度低于 20 ng/mL 则被视为缺乏。 TPA 水平与对照组处于相同范围，仅在 SLE 中升高。 HPRL、高铁蛋白血症、维生素 D 缺乏和 TPA 水平与 RA 中类风湿因子或抗 CCP 抗体水平升高的 SLE 活动无关。 HPRL、高铁蛋白血症和维生素 D 缺乏症在自身免疫性疾病的发病机制中具有不同的免疫学意义。在某些情况下，可以考虑使用维生素 D 进行预防性治疗或使用多巴胺激动剂治疗 HPRL。高铁蛋白血症可用作自身免疫性疾病（主要是 SLE）的急性时相反应物标志物。 TPA 可用于指示恶性肿瘤的倾向。
The development of autoimmune diseases maybe influenced by hormonal, immunomodulatory, and metabolic pathways. Prolactin (PRL), ferritin, vitamin D, and the tumor marker tissue polypeptide antigen (TPA) were measured in autoimmune diseases: systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), polymyositis (PM), dermatomyositis (DM), multiple sclerosis (MS), antoimmune thyroid diseases, and antiphospholipid syndrome. Hyperprolactinemia (HPRL) was detected in 24% of PM patients, in 21% of SLE patients, in 6.7% of MS patients, 6% of RA patients, and in 3% of SSc patients. Hyperferritinemia was detected in 23% of SLE patients, 15% of DM patients, 8% of MS patients, and 4% of RA patients. The patients had relatively low levels of 25 OH Vitamin D: the average results (mean +/- SD) were between 9.3 +/- 4.4 to 13.7 +/- 7.1 ng/mL in the different diseases, while the 25 OH Vitamin D concentrations less than 20 ng/mL are regarded as deficient. TPA levels were in the same range of the controls, elevated only in SLE. HPRL, hyperferritinemia, hypovitaminosis D, and TPA levels did not correlate with SLE activity elevated levels of rheumatoid factor or anti-CCP antibodies in RA. HPRL, hyperferritinemia, and hypovitaminosis D have different immunological implications in the pathogenesis of the autoimmune diseases. Preventive treatment with vitamin D or therapy for HPRL with dopamine agonists, may be considered in certain cases. Hyperferritinemia may be used as an acute-phase reactant marker in autoimmune diseases mainly SLE. TPA may be used to indicate the tendency for malignancies.